Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.74 |
| ▸ | F2 | P00734 | 4/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059203 | 0.95 | F10 (0.66) | F10F2THRB | |
| SCHEMBL2470814 | 0.94 | F10 (0.75) | F10F2THRB | |
| SCHEMBL2474406 | 0.93 | F10 (0.64) | F10F2THRB | |
| SCHEMBL2470810 | 0.93 | F10 (0.66) | F10F2THRB | |
| SCHEMBL2477850 | 0.89 | F10 (0.77) | F10F2THRB | |
| SCHEMBL2473205 | 0.88 | F10 (0.66) | F10F2THRB | |
| SCHEMBL3061731 | 0.87 | F10 (0.63) | F10F2THRB | |
| SCHEMBL2469005 | 0.85 | F10 (1.00) | F10F2 | |
| SCHEMBL3757872 | 0.85 | F10 (0.58) | F10F2THRB | |
| SCHEMBL2471758 | 0.85 | F10 (1.00) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846934-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8383822-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| EP-2170877-B1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| EP-2173744-B1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | Bayer Pharma AG (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057951-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F10 360/4885F2 30/4885THRB 3871/4885 |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F10 360/4885F2 30/4885THRB 3871/4885 |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F10 360/4885F2 30/4885THRB 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.